Insmed Incorporated Insmed Incorporated

Insmed Incorporated

INSM

株式のランク #1107
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
株価
$96.08
時価総額
$20.98B
変化(1日)
0.83%
変化(1年)
-42.78%
国
US
取引 Insmed Incorporated (INSM)

カテゴリー

Healthcare
Insmed Incorporated(INSM)のP/S比率
October 2026 時点のP/S比率 TTM: 18.77
Insmed Incorporated の最新の財務報告および株価によると、現在のP/S比率(TTM)は 18.77 です。2023 年末時点でのP/S比率は 14.26 でした。
Insmed Incorporated の P/S 比率の履歴(2000 ~ 2026)
各年末時点のP/S比率
年 P/S比率 変化
2026 (TTM) 18.77 -39.72%
2024 31.14 118.38%
2023 14.26 42.32%
2022 10.02 -38.17%
2021 16.20 -18.01%
2020 19.76 33.56%
2019 14.80 -85.57%
2018 102.51 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 -100.00%
2014 57.87 11.92%
2013 51.71 0.00%
2012 0.00 -100.00%
2011 16.12 33.50%
2010 12.08 27.98%
2009 9.44 93.34%
2008 4.88 -61.16%
2007 12.57 -85.15%
2006 84.64 -88.45%
2005 732.99 16.61%
2004 628.56 -10.83%
2003 704.88 9,371.65%
2002 7.44 -98.25%
2001 424.21 -59.94%
2000 1.06K 0.00%
同業他社のP/S比率
企業 P/S比率 P/S比率の差 国
10.02 -46.61%
US
40.55 116.02%
US
3.96 -78.90%
AU
- -
CH
10.15 -45.95%
NL